Leadership Transition - Cerus Corporation announced the appointment of Vivek Jayaraman as President and Chief Executive Officer, effective July 1, 2026, with William "Obi" Greenman transitioning to Executive Chairman of the Board [1][2] - The leadership change is part of a succession planning process aimed at preparing for the next phase of growth at Cerus [2] Executive Background - Vivek Jayaraman has been with Cerus since 2016, initially as Chief Commercial Officer and then as Chief Operating Officer since 2020, during which he helped grow annual product revenue from less than $40 million to over $200 million by 2025 [2][3] - Obi Greenman has served as CEO for over 15 years, transforming Cerus from a pre-clinical development company into a global commercial enterprise with product sales in over 40 countries [3][4] Future Goals - Vivek Jayaraman expressed his commitment to broadening patient access to the INTERCEPT Blood System globally, expanding leadership in transfusion medicine, and improving patient outcomes [3] - Obi Greenman highlighted the company's achievements, including four FDA product approvals in the past decade and a robust innovation pipeline, positioning Cerus well for future growth [4] Company Overview - Cerus Corporation is dedicated to safeguarding the world's blood supply and aims to become the leading global blood products company, developing technologies and pathogen-protected blood components [8] - The INTERCEPT Blood System is the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma, with ongoing regulatory review for the red blood cell system in Europe [8]

Financial Data and Key Metrics Changes - The company achieved a positive non-GAAP adjusted EBITDA for 2024 and is committed to maintaining this for 2025, indicating an improving financial profile [7][42] - Current revenue guidance for 2025 is between $194 million to $200 million, representing a sub-10% penetration of the total addressable market (TAM) of $2.5 billion for existing licensed products [8][11] Business Line Data and Key Metrics Changes - The INTERCEPT Fibrinogen Complex product is projected to generate $12 million to $15 million in revenue for 2025, showing significant growth potential [11][31] - The INTERCEPT technology has been developed to treat all four transfused blood components: platelets, plasma, red cells, and fibrinogen complex, with a strong market presence in the platelet transfusion sector [4][5] Market Data and Key Metrics Changes - The total addressable market for the platelet opportunity is expected to reach at least $1.5 billion by 2030, with organic growth in the platelet market typically ranging from 3% to 5% annually [9][10] - The red cell market opportunity is the largest, estimated at $5 billion globally, highlighting the importance of getting the INTERCEPT Red Cell program approved [10] Company Strategy and Development Direction - The company aims to extend its leadership position in the INTERCEPT blood system for platelets and plasma, targeting additional market share in the U.S. and expanding into markets like China, Brazil, and Germany [42][43] - The focus is on developing real-world outcomes data for the INTERCEPT Fibrinogen Complex and targeting international opportunities [44] Management's Comments on Operating Environment and Future Outlook - Management emphasized the strong and improving financial profile, with sustained revenue growth expected through the end of the decade due to existing and new products [7][42] - The company is well-positioned to leverage its established customer base and recurring revenue model to drive growth [5][6] Other Important Information - The company has a strong cash position, which supports its growth initiatives and operational stability [7] - The INTERCEPT technology addresses significant unmet needs in transfusion medicine, particularly in pathogen reduction and safety [15][18] Q&A Session Summary Question: What is the outlook for the INTERCEPT Red Cell program? - The company is nearing completion of enrollment for the ReCePI study in the U.S., which is required for the PMA submission with the FDA [34] Question: How is the INTERCEPT Fibrinogen Complex performing in the market? - The product is gaining traction in major academic hospitals, with a projected revenue of $12 million to $15 million for 2025 and a significant market opportunity in the U.S. [31][32]